I'm not a good resource for that kind of information.
In my brain, I think about these small Biotech R&D companies in the same way i think about small precious metals Exploration companies.
Management is always trying to raise new money for the next drill program. The big spenders might buy "Preferred Shares" that can be converted later into Common shares. Either way, the Company has to make all of those transactions public knowledge.
Surely AXIM is forced to clear up the Derivative Liability insufficient shares mess by EOY reporting. ( I hope. ).